SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
FRA:1SXP - DE000A3ENQ51 - Common Stock
23 EUR
-0.4 (-1.71%)
We assign a fundamental rating of 5 out of 10 to 1SXP. 1SXP was compared to 18 industry peers in the Life Sciences Tools & Services industry. While 1SXP belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. 1SXP is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 1SXP was profitable.
1SXP had a positive operating cash flow in the past year.
In the past 5 years 1SXP has always been profitable.
Each year in the past 5 years 1SXP had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 9.61%, 1SXP belongs to the best of the industry, outperforming 94.44% of the companies in the same industry.
With an excellent Return On Equity value of 17.01%, 1SXP belongs to the best of the industry, outperforming 94.44% of the companies in the same industry.
1SXP's Return On Invested Capital of 13.93% is amongst the best of the industry. 1SXP outperforms 100.00% of its industry peers.
1SXP had an Average Return On Invested Capital over the past 3 years of 15.68%. This is significantly above the industry average of 7.13%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.01% | ||
| ROIC | 13.93% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
1.3 Margins
1SXP has a better Profit Margin (15.05%) than 77.78% of its industry peers.
1SXP's Profit Margin has been stable in the last couple of years.
The Operating Margin of 1SXP (19.47%) is better than 77.78% of its industry peers.
In the last couple of years the Operating Margin of 1SXP has grown nicely.
1SXP's Gross Margin of 33.73% is in line compared to the rest of the industry. 1SXP outperforms 44.44% of its industry peers.
In the last couple of years the Gross Margin of 1SXP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.47% | ||
| PM (TTM) | 15.05% | ||
| GM | 33.73% |
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 1SXP is creating value.
The number of shares outstanding for 1SXP remains at a similar level compared to 1 year ago.
1SXP has a worse debt/assets ratio than last year.
2.2 Solvency
1SXP has a debt to FCF ratio of 1.74. This is a very positive value and a sign of high solvency as it would only need 1.74 years to pay back of all of its debts.
1SXP's Debt to FCF ratio of 1.74 is amongst the best of the industry. 1SXP outperforms 100.00% of its industry peers.
1SXP has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of 1SXP (0.09) is better than 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.74 | ||
| Altman-Z | N/A |
ROIC/WACC1.8
WACC7.75%
2.3 Liquidity
1SXP has a Current Ratio of 1.57. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
1SXP has a Current ratio (1.57) which is comparable to the rest of the industry.
1SXP has a Quick Ratio of 1.17. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.17, 1SXP is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The earnings per share for 1SXP have decreased by -3.00% in the last year.
The Earnings Per Share has been growing by 14.04% on average over the past years. This is quite good.
1SXP shows a small growth in Revenue. In the last year, the Revenue has grown by 2.86%.
Measured over the past years, 1SXP shows a quite strong growth in Revenue. The Revenue has been growing by 13.84% on average per year.
EPS 1Y (TTM)-3%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-3.23%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
3.2 Future
The Earnings Per Share is expected to grow by 10.56% on average over the next years. This is quite good.
1SXP is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.80% yearly.
EPS Next Y4.64%
EPS Next 2Y10.58%
EPS Next 3Y12.5%
EPS Next 5Y10.56%
Revenue Next Year3.42%
Revenue Next 2Y6.56%
Revenue Next 3Y8.07%
Revenue Next 5Y7.8%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
1SXP is valuated rather expensively with a Price/Earnings ratio of 23.71.
Compared to the rest of the industry, the Price/Earnings ratio of 1SXP indicates a somewhat cheap valuation: 1SXP is cheaper than 61.11% of the companies listed in the same industry.
1SXP is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.14, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 19.00, which indicates a rather expensive current valuation of 1SXP.
1SXP's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. 1SXP is cheaper than 72.22% of the companies in the same industry.
1SXP is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.80, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.71 | ||
| Fwd PE | 19 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1SXP is valued a bit cheaper than the industry average as 77.78% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, 1SXP is valued a bit more expensive than 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 69.88 | ||
| EV/EBITDA | 13.4 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1SXP does not grow enough to justify the current Price/Earnings ratio.
1SXP has an outstanding profitability rating, which may justify a higher PE ratio.
1SXP's earnings are expected to grow with 12.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)5.12
PEG (5Y)N/A
EPS Next 2Y10.58%
EPS Next 3Y12.5%
5. Dividend
5.1 Amount
With a yearly dividend of 0.68%, 1SXP is not a good candidate for dividend investing.
1SXP's Dividend Yield is a higher than the industry average which is at 0.70.
With a Dividend Yield of 0.68, 1SXP pays less dividend than the S&P500 average, which is at 2.34.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.68% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
16.41% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.41%
EPS Next 2Y10.58%
EPS Next 3Y12.5%
FRA:1SXP (8/28/2025, 5:29:51 PM)
23
-0.4 (-1.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners19.43%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.46B
Analysts76.84
Price Target29.89 (29.96%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.68% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.41%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.21%
Min EPS beat(2)-1.05%
Max EPS beat(2)5.48%
EPS beat(4)1
Avg EPS beat(4)-5.25%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)4
Avg EPS beat(8)6.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)1.75%
Revenue beat(4)1
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.93%
PT rev (3m)3.16%
EPS NQ rev (1m)-12.9%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.29%
EPS NY rev (3m)-0.29%
Revenue NQ rev (1m)-6.07%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.73%
Revenue NY rev (3m)-1.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.71 | ||
| Fwd PE | 19 | ||
| P/S | 3.55 | ||
| P/FCF | 69.88 | ||
| P/OCF | 17.02 | ||
| P/B | 4.01 | ||
| P/tB | 4.16 | ||
| EV/EBITDA | 13.4 |
EPS(TTM)0.97
EY4.22%
EPS(NY)1.21
Fwd EY5.26%
FCF(TTM)0.33
FCFY1.43%
OCF(TTM)1.35
OCFY5.88%
SpS6.48
BVpS5.73
TBVpS5.53
PEG (NY)5.12
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.01% | ||
| ROCE | 17.04% | ||
| ROIC | 13.93% | ||
| ROICexc | 14.46% | ||
| ROICexgc | 14.87% | ||
| OM | 19.47% | ||
| PM (TTM) | 15.05% | ||
| GM | 33.73% | ||
| FCFM | 5.08% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
ROICexc(3y)16.18%
ROICexc(5y)17.77%
ROICexgc(3y)16.78%
ROICexgc(5y)18.78%
ROCE(3y)19.2%
ROCE(5y)20.87%
ROICexcg growth 3Y-8.59%
ROICexcg growth 5YN/A
ROICexc growth 3Y-7.46%
ROICexc growth 5YN/A
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.74 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 204.37% | ||
| Cap/Sales | 15.78% | ||
| Interest Coverage | 12.16 | ||
| Cash Conversion | 76.71% | ||
| Profit Quality | 33.75% | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | N/A |
F-Score5
WACC7.75%
ROIC/WACC1.8
Cap/Depr(3y)291.84%
Cap/Depr(5y)279.9%
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.98%
Profit Quality(5y)27.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-3%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%-3.23%
EPS Next Y4.64%
EPS Next 2Y10.58%
EPS Next 3Y12.5%
EPS Next 5Y10.56%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
Revenue Next Year3.42%
Revenue Next 2Y6.56%
Revenue Next 3Y8.07%
Revenue Next 5Y7.8%
EBIT growth 1Y12.19%
EBIT growth 3Y18.37%
EBIT growth 5YN/A
EBIT Next Year39.55%
EBIT Next 3Y25.42%
EBIT Next 5Y18.01%
FCF growth 1Y-28.77%
FCF growth 3Y33.55%
FCF growth 5YN/A
OCF growth 1Y-5.41%
OCF growth 3Y19.45%
OCF growth 5YN/A